In a recent phase 3 study published The Lancet Respiratory Medicine, scientists assessed the potential of tixagevimab–cilgavimab for treating hospitalized severe acute respiratory syndrome coronavirus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback